![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PONIARD BEGINS TRIAL OF PICOPLATIN FOR LUNG CANCER
PONIARD BEGINS TRIAL OF PICOPLATIN FOR LUNG CANCER
August 21, 2006
Poniard Pharmaceuticals has completed enrollment in a Phase II, open-label, multicenter trial evaluating picoplatin for the treatment of small-cell lung cancer. All 75 patients targeted for enrollment have been treated with picoplatin.
Picoplatin is an intravenous chemotherapeutic agent designed to overcome platinum resistance associated with the treatment of solid tumors. Testing in more than 500 patients in Phase I and II safety and efficacy studies indicated that picoplatin may have a more manageable safety profile with fewer side effects than currently available platinum-based therapies. In addition to this Phase II trial, picoplatin is being studied in patients with colorectal and prostate cancers. The FDA has granted the drug orphan drug status for small-cell lung cancer.
Small-cell lung cancer is currently treated with platinum therapies, but many patients do not respond or relapse within a short time of treatment. According to the 2006 National Comprehensive Cancer Network practice guidelines in oncology, the median survival for patients who receive second-line chemotherapy is approximately 16 to 20 weeks, while median survival for patients who progress or relapse and do not receive second-line chemotherapy is approximately 14 weeks.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct